Owlstone Medical recruits first patient in phase 2 clinical trial for the early detection of lung cancer through breath biopsy

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced recruitment of the first patient into its EVOLUTION Phase 2 clinical trial following successful achievement of key safety and proof of concept milestones in Phase 1.

Study links higher-potency cannabis use in youth to increased risk of psychotic experiences

Young individuals consuming higher-potency cannabis, such as skunk, between ages 16 and 18, are twice as likely to have psychotic experiences from age 19 to

May 14, 2024

Neumora’s major depression drug flunks first of three Phase 3 trials

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

January 3, 2025

GE HealthCare Receives FDA Clearance for SIGNA™ MAGNUS Head-Only MRI Scanner

What You Should Know: – GE HealthCare (Nasdaq: GEHC) has received FDA 510(k) clearance for its innovative SIGNA™ MAGNUS, a 3.0T high-performance, head-only magnetic resonance imaging (MRI)

November 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.